Clinical Trials Browser

INDUSTRY × nintedanib × Thoracic × Clear all

NCT02231164 2025-02-13

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Phase 3 Terminated

12 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT01346540 2025-02-12

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Phase 1 Completed

16 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT02300298 2025-02-11

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Phase 1 Completed

10 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02668393 2021-01-29

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

Phase 1 Completed

14 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Phase 2/3 Terminated

545 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02751385 2019-03-14

Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Phase 1 Terminated

2 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT00805194 2018-12-05

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Phase 3 Completed

1,314 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT00806819 2017-02-02

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Phase 3 Completed

718 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02182102 2014-07-18

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung